Related Experiment Videos
[Angiogenesis and antitumor therapy]
F Ferrara1, M Falchi, S Puricelli
1Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano.
Abstract:
We have examined the most recent literature dealing with the relationship between tumor growth and neovascularization (tumoral neoangiogenesis). It is quite evident that antiangiogenic therapy against solid tumors has an important theoretical basis. Many antiangiogenic substances are presently under study, and some inhibitors of angiogenesis, such as TNP-740, platelet factor 4, linomide, tecogalan, etc., are currently being tested in phase 1 or 2 clinical trials. These studies have, however, underscored the possibility of numerous side effects due to the lack of specificity of these substances against endothelial cells. The most promising and rational use of antiangiogenic factors in anticancer therapy seems to be their association with traditional chemo- or radiotherapy. Gene therapy also offers considerable theoretical promise as demonstrated by the transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line.
Insights
Antiangiogenic therapy shows promise for solid tumors by inhibiting tumor blood vessel growth. Combining antiangiogenic factors with traditional treatments like chemotherapy or radiotherapy may offer the most effective anticancer strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Context:
- Tumor growth is critically dependent on neovascularization, also known as tumoral neoangiogenesis.
- Antiangiogenic therapy presents a theoretically sound approach to combatting solid tumors.
- Numerous antiangiogenic substances are under investigation, with some inhibitors entering early-phase clinical trials.
Purpose:
- To review the current literature on the relationship between tumor growth and neovascularization.
- To evaluate the potential and challenges of antiangiogenic therapy in cancer treatment.
- To explore novel therapeutic strategies, including combination therapies and gene therapy.
Summary:
- Recent literature highlights the link between tumor growth and neovascularization, supporting the rationale for antiangiogenic therapy.
- While several antiangiogenic inhibitors are in clinical trials, concerns exist regarding their specificity and potential side effects.
- Combining antiangiogenic factors with conventional chemotherapy or radiotherapy is considered a promising strategy.
- Gene therapy, exemplified by the transfection of thrombospondin 1 complementary DNA, also shows potential.
Impact:
- Antiangiogenic therapy offers a novel mechanism to target solid tumors by disrupting their blood supply.
- Understanding the limitations and side effects of current antiangiogenic agents is crucial for safe and effective clinical application.
- Combination approaches and gene therapy represent future directions for enhancing anticancer efficacy and overcoming resistance.